We are live on ! Find out more
MYOV

Myovant Sciences

Delisted

MYOV was delisted on the 9th of March, 2023.

42 hedge funds and large institutions have $575M invested in Myovant Sciences in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital inflows, than outflows

Capital inflows: $16.9M | Capital outflows: $15.9M

0.07% more ownership

Funds ownership: 81.52% → 81.59% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

13% less funds holding

Funds holding: 48 → 42 (-6)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

Holders
42
Holders Change
-6
Holders Change %
-12.5%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
11
Reduced
12
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MYOV Hedge Fund Activity: Q2 2017 in Review

42 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Myovant Sciences (MYOV) for Q2 2017, worth a combined $575M — down 0.22% from $577M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of MYOV and 12 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 11 added.

The largest buyer was RA Capital Management, adding an estimated $5.69M. The largest seller was BlackRock, cutting an estimated $4.55M.

  • 42 institutional investors held Myovant Sciences (MYOV) as of Q2 2017, down from 48 in Q1 2017.
  • Funds reported $575M of Myovant Sciences stock for Q2 2017, down 0.22% quarter-over-quarter.
  • 12 funds opened new Myovant Sciences positions in Q2 2017 and 18 closed out, a net change of -6 holders.
  • The largest Myovant Sciences buyer in Q2 2017 was RA Capital Management, an estimated $5.69M added.
  • The largest Myovant Sciences seller in Q2 2017 was BlackRock, an estimated $4.55M sold.

Based on aggregated 13F filings for Q2 2017.